+

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| Substitute for form 1449A/PTO | | Complete if Known | | | | | |
|--|-----------------------|-------------------|--|--|--|--|--|
| INFORMATION DISCL PE CSTATEMENT BY APP (use as many sheets as nece | LICANT | 09/445,865 | | | | | |
| (use as many sheets as nece | Filing Date | February 11, 2000 | | | | | |
| MAY S | First Named Inventor | Philip John Burke | | | | | |
| MAN STEMBER TRADERS | Group Art Unit | 1643 | | | | | |
| Array a TRADE | Examiner Name | | | | | | |
| Sheet 1 of | 9 Attorney Docket Nun | nber ERD 100 | | | | | |

| | | | | U.S. PATENT DOCUMEN | 118 | |
|---------------------------------------|--------------|---------------|---|--|--|--|
| Examiner Cite US Patent Document No.1 | | ment | Name of Patentee or Applicant of Cited Document | Date of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | |
| | ļ | | Code ² known) | | | |
| | | 4,440,859 | | Rutter,-et-al, | 04-03-1984 | |
| | | 4,530,901 | APRICE AND APRICES | Weissmann | 07-23-1985 | F146(37)F |
| CALLED LANGE | | 4,582,800 | COLUMN TO SERVE | Grow - was a man or | 04-15-1986 | |
| | | 4,67.7.,063 | | Marky-et-al minimum substitution communication and the second sec | 06-30-1987 | SERVED SERVED |
| | | 4,678,751 | | | 07-07-1987 | THE PROPERTY OF THE PROPERTY O |
| 9-10-11-14-29-1976 | ar Dipatent | 4;704;362 | 建设实现 超级 | | 11-03-1987 | |
| 4 45 6 1 | Land touches | 4,710,463 | 1.245.35% | Murray | 1-2-01-1987 | STEARTS STEAR STEA |
| . 31 - Ap., No. oc | | 4.757.006 | | Tooley Jr. et along | 07-12-1988 | CONTROL OF THE PROPERTY OF THE |
| | | 4;766;075==== | SHIP C | Goeddel et al | 08-23-1988 | newspapers. |
| WANTE CONTRACTOR | and the | 4,810,648 | at Action was | Stälker | 03:07:1989 | BEETING . |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | - | | | |
| | | | | | | |
| | | | | | | |
| | | - | | | | |
| | | | Ţ | | | |
| | | | <u> </u> | | | |
| | - | | | | | |
| | - | | | | | |

| | | | ᠘ | | |
|----------------------|---------------|-----------------|----|-----|----|
| Examine Signature | (Burn Boutle | Date Considered | /2 | 2/0 | 01 |
| Oignature | | | _ | 7 | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

| Please type a | plus | sign | (+) inside | this | $box \rightarrow$ |
|---------------|------|------|------------|------|-------------------|

| | PTO/SB/08A (10-9 | 96 |
|--------------|---|----|
| | Approved for use through 10/31/99. OMB 0651-003 | |
| Patent and T | ademark Office: U.S. DEPARTMENT OF COMMERC | |

| Substitute for form 1449A/PTO | Complete if Known | | | | | |
|---|------------------------|-------------------|--|--|--|--|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Application Number | 09/445,865 | | | | |
| (use as many sheets as necessary) | Filing Date | February 11, 2000 | | | | |
| (use as many sheets as necessary) | First Named Inventor | Philip John Burke | | | | |
| MAY | Group Art Unit | 1643 | | | | |
| | Examiner Name | | | | | |
| of 9 | Attorney Docket Number | ERD 100 | | | | |

| | | | | F | OREIGN PATENT DOCUMENT | | | |
|---|--|-------------------------|------------|--------------------------|--|--------------|--|----|
| xaminer Initials* | Cite No.1 | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document C | | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
| | | Office.3 | | Kind Code⁵ (if known) | | | | |
| 2000 P | and the same | EP | 0.251.744 | A2: | Delta-Biotechnology-Ltd: | 01-07-1988 | 3 Charles | |
| CHICAGO, | المستنشئة | ERسنف | 0.258:067 | A2sminener | Delta:Biotechnology:Ltd: | 03:02:4988 | | |
| الانا يتوسينانك | Bridge of 4 | EP :> | 0 302 473 | A2 | Bristol*Myers Co: | 02-08-1989 | THE REPORT OF THE PARTY OF THE | |
| and the same | a marine marine. | EP | 0.415,731 | | The:Wellcome,Foundation | 03-06-1991- | | |
| | , was a substitute of | هشتس O _. W | 88/07/37/8 | Astronomo | Cancer/Research/Campaign | 1.0-06-1:988 | S-PC-Spharon Strate Str | |
| CEE | - NEW TOP | WO | 89/10140, | A1 | Cancer Research Campaign Technology Ltd! | 11-02-1989 | No appropriate the second | |
| TOS COLUMN | \$2353939 | WO ^{∴®} | 90/01063 | A462ECE/SC3 | Delta Biotechnology Ltd. | 02-08-1990 | A THE THE PROPERTY OF THE PARTY | Ĺ |
| | | wo | 91/09867 | A1 | Imperial Cancer Research Technology Ltd. | 07-11-1991 | and a section of the | İ |
| | -2007-20 | wo | 91/11201 | A1 | Imperial Cancer Research | 08-07-1991 | TO SECURE DESCRIPTION OF THE PROPERTY OF THE P | |
| GN | | wo | 93/08288 | A1 | Technology Ltd. | 04-29-1993 | | L |
| · Comment | | MOzne | 93/43805 | Adama | Bagshawe | | | |
| * TOPPOSITE | CENTRAL PROPERTY. | W0×× | 93/1:3806 | A.1. | Bagshawe | 07-22-1993 | NEW CONTRACTOR | |
| GW | | wo | | A1 | Cancer Research Campaign Technology Ltd. | 05-11-1995 | | Ĺ_ |
| GN | | wo | 97/07097 | A1 | Auckland Division Cancer Society of New Zealand | 02-27-1997 | | |
| GN | 1 | wo | 97/24143 | A1 | AEPACT, Ltd. | 07-10-1997 | | |
| Accessories to | · received (12) | WO: | 97/20580 | Adametrae | AEPACT Ltd: | 06-12-1997 | | |
| house | - | | 97/24143 | | AEPAGT; Ltd. | 07-10-1997 | THE WITCHEST | |
| GN | | wo | 98/22577 | A1 | Masucci | 05-28-1998 | | |
| CONTRACTOR OF THE PARTY OF THE | - WOODS | WO*** | 98/24478 | A2 | AERACT, Ltd | 06-11-1998 | | |

| | • | | | | |
|----------------------|--|-----------------|----|----|--|
| Examine Signature | (surposite | Date Considered | 2/ | 01 | |
| U.g. atter | CY OF THE PROPERTY OF THE PROP | | | - | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant to place a check mark here if English language Translation is attached.

| PTO/SB/08A (10-96 | |
|--|---|
| Approved for use through 10/31/99. OMB 0651-0031 | • |
| nd Trademark Office: U.S. DEPARTMENT OF COMMERCE | |

| Substitute for form 1449A/PTO | Complete if Known | | | | |
|---|------------------------|-------------------|--|--|--|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Application Number | 09/445,865 | | | |
| 3 (ass as many should be necessary) | Filing Date | February 11, 2000 | | | |
| O LANGE | First Named Inventor | Philip John Burke | | | |
| MRI DE LEGICIONE | Group Art Unit | 1643 | | | |
| ` | Examiner Name | | | | |
| NV# | Attorney Docket Number | ERD 100 | | | |

| | - | OTHER ART NON PATENT LITERATURE DOCUMENTS | |
|--|--|---|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T [*] |
| | | ANLEZARK, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)1. Purification and properties of a nitroreductase enzyme from Escherichia collar potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT)," Biochem. Pharmacol. 1992 44(12):2289-95. | |
| homen | (Control of the Control of the Contr | BETTER, et al., "Escherichia coli secretion of an active chimeric antibody fragment," Science 240(4855):1041-43 (1988). | |
| | | BIRD, et al., "Single-chain antigen-binding proteins," Science 242(4877):423-26 (1988). | |
| y construction | | 大学院是是是不要的人的人,也可以是是一个人的人,但是是不要的人的人的人,也是是一个人的人的人的人的人的人的人的人的人的人,但是是一个人的人的人的人的人的人,也不 | <u> </u> |
| i <u>elen</u> lielend | عنشنا أوالما | BISCHOFF, et al., "An adenovirus mutant that replicates selectively in p53-deficient human tumor cells," Science 27.4(5286):373-765(4)996) | |
| **CONTRACTOR OF THE PARTY OF TH | har of the | BOLAND, et al., "The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)," Biochem. Pharmacol. 41(6-7):867-75 (1991). | |
| 100 | ciatas. | BRADL, et al., "Malignant melanoma in transgenic mice," Proc. Natl. Acad. Sci. U. S. A. 88(1):164-68 (1991). | |
| | ES SE | BRAWER, "Prostate specific antigen Arreview," Acta. Oncol. 30(2):161-68 (1991). | |
| THE PROPERTY. | ZVEVE | CHEN, et al., "Expression of rat liver NAD(P)H:quinone-acceptor oxidoreductase in Escherichia coli and mutagenesis in vitro at Arg-177," Biochem. J. 284 (Pr.3):855-60 (1992). | |
| ************************************** | PERME | CHEN, et al., "Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse," J. Biol. Chem. 272(3):1437-39 (1997). | |
| 7 | श्वका | CLARK, etal; "Role of the Bp35 cell surface polypentide in human B-cell activation," Proc. Natl. Acad. Sci. U. S. A. 82(6):1766-70 (1985). | |

| | | | | | 1 | | | |
|-------------------------|-----------|-------------|-----------------|----|----|----|---|------|
| Examiner's Signature | ankon | | Date Considered | 4/ | 2/ | 10 | / | |
| | p a v | | | | | | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

| _ | ŀ |
|---|---|
| | • |

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known Application Number 09/445,865 INFORMATION DISCLOSURE COSTATEMENT BY APPLICANT use as many sheets as necessary) February 11, 2000 Filing Date First Named Inventor Philip John Burke 1643 **Group Art Unit** Examiner Name ERD 100 Attorney Docket Number 9 of

| | | OTHER ART - NON PATENT LITERATURE DOCUMENTS | |
|-------------------------|--------------|---|----|
| Examiner's Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | 1- |
| | | CONNORS & WISSON, "Cure of mice-bearing-advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity," Nature 210(38):866-67 (1966). | |
| Palestan S. | Section | CORVALAN & SMITH, "Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembigonic antigen (SEA) and vine a alkaloids. ************************************ | |
| Carlo State | TO ORDER | CORVALAN, et al., "Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody;" Cancer Immunother::24(2):4:38:43:(1987). | |
| | A STEROMENTS | CORVALAN, et al., "Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (GEA), and vinca alkaloids," Cancer Immunol. Immunother. 24(2):133-37 (1987). | |
| *********** | | COTTEN, et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles," <i>Proc. Natl. Acad. Sci. U. S.</i> [4, 89(13):6094-98 (1992). | |
| 10203 | : GENTRAS | A. 89(13):6094-98 (1992). COUSSENS, et al., "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene," Science 230(4730):1132-39 (1985). | |
| NACO FEE COM | į. | CULVER, et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," Science 256(5063):1550-52 (1992). | |
| *HIMMET | - 05000 | CURIEL "Adenovirus facilitation of molecular conjugate mediated gene transfer," Prog. Med. Virol. 40:1-18 (1993). | |
| GW | | DRABEK, et al., "The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954," <i>Gene Ther.</i> 4(2):93-100 (1997). | |
| GN | | FRIEDLOS & KNOX, "Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system," <i>Biochem. Pharmacol.</i> 44(4):631-35 (1992). | |

| | | | | • | · · · · · · · · · · · · · · · · · · · |
|------------|---|-----------------|--|----------|---------------------------------------|
| Examiner's | | Date Considered | 1// | \sim 1 | |
| | | | \vee \prime | | ' /) / |
| Signature | | ! ! | 1.7 | ~ I | <u> </u> |
| Oignatu.0 | | | - | | |
| | 1 | | • | , | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

| Please type a plus sign (+) inside this box | → | |
|---|----------|--|
|---|----------|--|

| PTO/SB/08A (10-9 |
|--|
| Approved for use through 10/31/99. OMB 0651-003 |
| Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE |

| Substitute for form 1449A/PTO | · Co | omplete if Known |
|---|-------------------------|-------------------|
| INFORMATION DISCLOSURE TO STATEMENT BY APPLICANT Use as many sheets as necessary) | Application Number | 09/445,865 |
| J1 (V U) | Filing Date | February 11, 2000 |
| MAT S | First Named Inventor | Philip John Burke |
| | Group Art Unit | 1643 |
| WATENT & THOSE | Examiner Name | |
| Sheet 5 of 0 | Attornou Doolsof Number | EDD 400 |

| | | OTHER ART – NON PATENT LITERATURE DOCUMENTS | |
|-------------------------|--------------------------|--|---|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T |
| | | FRIEDLOS, et al., "Identification of novel-reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2)," Biochem. Pharmacol. 44(1):25-31 (1992). | |
| Constituti | | FRIEDLOS, et al., "Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity," Biochem, Pharmacol. 44(9):1739-43 (1992). | |
| Oncorre | ur esta de | GILLILAND, et al., "Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells," Proc. Natl-Acad Sci. U. S. A. 85(20):77 19 23 (1988) | |
| GN | | GREEN, et al., "Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene," Cancer Gene Ther. 4(4):229-38 (1997). | - |
| ,ee: | TEXES. | HARWOOD, et al., "Comparative tumour localization of antibody fragments and intact IgG in nude mice bearing a GEA-producing human colon tumour xenograft," Eur. J. Cancer Clin. Oncol. 21(12):1515-22 (1985). | |
| 02020 | | HELLSTRÖM, et al. "Monoclonal mouse antibodies raised against human lung carcinoma," Cancer Res. 46(8):3917- 23"(1986). | |
| ં± જી. જો | | HURRELL, "Monoclonal Hybridoma Antibodies: Techniques and Applications," (CRC Press). | |
| COLUMN E | CLEM, | HUSTON, et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coll, "Proc. Natl. Acad. Sci. U. S. A. 85(16):5879-83 (1988). | |
| فأشفية بريو يموس | ide leav | JACKSON, et al., "The tyrosinase-related protein-1 gene has a structure and promoter sequence very different from tyrosinase," Nucleic Acids Res (1.4):37.99-804x(4.991) | |
| e de la compa | TOWN 10 | JAISWAL, "Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression," J. Biol. Chem. 269(20):14502-08 (1994). | |

| | | // | 1 |
|------------|----------------|---------------------|-------|
| Examiner's | Ca Par Chi | Date Considered U/o | 101 |
| Signature | / MUNTY NULLUX | 1 1/2 | . 101 |
| | 9 | | / |
| | | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

| Please type a plus sign (+) inside this box → | + | Ì |
|---|---|---|
| | | |

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 09/445,865 **STATEMENT BY APPLICANT** e as many sheets as necessary) Filing Date February 11, 2000 First Named Inventor Philip John Burke **Group Art Unit** 1643 **Examiner Name** of 9 Attorney Docket Number **ERD 100**

| | - | OTHER ART NON PATENT LITERATURE DOCUMENTS | |
|---|--|--|----------------|
| Examiner's | Cite | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the | |
| Initials* | No.1 | item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), | T ² |
| | | publisher, city and/or country where published | |
| | | JAISWAL, "Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second | |
| Manage and and a | - Charles | member of the NATIPH autona | |
| | | member of the NAD(P)H:quinone oxidoreductase gene family Extensive polymorphism at the NQO2 gene locus on chromosome 6," Biochemistry. 29(7):1899-906 (1990). | ĺ |
| | ├── | | |
| entropy policies | بالدخانة فتك | KHAN & ROSS, "Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity | |
| | | relationships, Chem. Biol. Interact. 1(1):27-47 (1969). | ĺ |
| | ļ | | J |
| | | KNOX, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)II. A comparison of an Escherichia | |
| TATEL | First Co. | coll nitroreductase and Walker DT diaphorase; Biochem, Pharmacol. 44(12):2297-301 (1992). | f |
| | | | |
| 0 I | [| KNOX, et al., "The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy | |
| 120 | l | (ADEPT)," Cancer Metastasis Rev. 12(2):195-212 (1993). | 1 |
| | | 12/2/100 Z.12 (1000). | - 1 |
| | | KNOX, et al., "Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated | |
| 777388 | TO SECOND | produits in antibody and a strength of the str | Ì |
| 4.00.00 | | prodrugs in antibody directed enzyme prodrug therapy (ADEPT)," Biochem. Pharmacol. 49(11):1641-47 (1995). | - 1 |
| | | | |
| | e estable | KURIYAMA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a | |
| 7.125 Line | C. Micheles Lat | retroviral vector, Cell Struct. Funct. 16(6):503-10 (1991). | - 1 |
| | | | |
| 2333 | <u> ಆರ್ಥನಿಕ್ಕಾ</u> | LEDLEX: Nonviral gene therapy: the promise of genesias pharmaceutical products," Hum. Gene Ther. 6(9):1129-44 | |
| N. B. S. B. L. S. C. | | (1995). | |
| | | | |
| ļ | ï | LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," | |
| | | Biochem and Biophys Res Comm 4:208-13 (1961) | - 1 |
| *************************************** | A PARTIES AND A | The state of the s | |
| | | IAO & WILLIAMS-ASHMAN "Inhibition of the angustics of the angustic of the angustics of the | i |
| 12002945 | PERCHA | LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic mydrocarbons," Biochem. Pharmacol. 6:53-54 (1961). | |
| | 1 | Nydrodalbons, Biochem. Fnarmacoi. 6:53-54 (1961). | |
| | | IAO as all WD 16 | ĺ |
| | | LIAO, et al., "Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide," J. | |
| 148CORECTOR | The state of the s | Biol. Chem. 237 2984-87 (4962) | J |
| | | | - 1 |
| | | | |

| | | | | | | , |
|------------|--|-------------------|----|------|---|---|
| Examiner's | T / | | .7 | | | ш |
| Signature | (Frankisto | Date Considered 4 | 72 | 1/2 | 1 | |
| | The state of the s | // | /_ | ./0_ | | |
| *EYAMINED. | Initial if reference and the state of the st | | | / | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of Translation is attached.

| Please type a plus sign (+) inside this box \rightarrow | + | l |
|---|----|---|
| Please type a plus sign (+) inside this box \rightarrow | ١. | l |

of

9

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ERD 100

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

Application Number

O9/445,865

Filling Date
First Named Inventor
Group Art Unit
Examiner Name

Attorney Docket Number

| - | Lau | OTHER ART - NON PATENT LITERATURE DOCUMENTS | _ |
|---|-------------------|--|----|
| xaminers | Cite | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the | т- |
| Initials* | No.1 | item (ооок, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) | ļ |
| | L | L publisher, city and/or country where published | 1 |
| | l | LUNDWALL, "Characterization of the gene for prostate-specific antigen, a human glandular kallikrein," Biochem. | ╄ |
| | - markhaletar | Rionbys. Res. Commun. 161(3):1151-9 (1989) | l |
| | | 77007 | ı |
| | | MARTIN & PAPAHA IOPOULOS et al. "Issuerible and in the control of | L |
| | | MARTIN & PAPAHAJOPOULOS, et al., "Irreversible coupling of immunoglobulin fragments to preformed vesicles. An | Ì |
| | Zu. | improved method: for liposome targeting J. Biol. Chem. 257(1): 286-8 (1982). | l |
| | | | 1 |
| | Ī | MAUGER, et al., "Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction | - |
| SUCTOMATIONS | arten. | with a nitroreductase enzyme," J. Med. Chem. 37(21):3452-58 (1994) | ı |
| | | with a nitroreductase enzyme," J. Med. Chem. 37(21):3452-58 (1994). | |
| | | MICHAEL, et al., "Addition of a short peptide ligand to the adenovirus fiber protein," Gene Ther. 2(9):660-68 (1995). | L |
| | المائد فالمؤترة | 1995). | |
| , | | The state of the s | |
| | | | |
| | | MILLER & VILE, "Targeted vectors for gene therapy," FASEB J. 9(2):190-99 (1995). | _ |
| عارمته مناقا | MARKET SEE | | |
| | | | |
| | | MORRISON, et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region | _ |
| 2008年1月1日 | ANTERNA . | domains," Proc. Natl. Acad. Sci. U. S. A. 81(21):6851-55 (1984). | |
| | | 110001-05 (10001-05) | |
| | | NASSANDER et al. "In vivo torestina et OV TI 0" | |
| PROTECTION OF THE PARTY OF THE | The section | in vivo targeting of UV-1L 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in | |
| | | NASSANDER, et al., "In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice," Cancer Res. 52(3):646-53 (1992). | |
| | | · | |
| 1 | | NEUBERGER, et al., "Recombinant antibodies possessing novel effector functions," Nature 312(5995):604-08 | - |
| C) TO SEC MAR! | C 4055-308 | (1984). Wature 312(5995):604-08 | |
| - 1 | | | |
| | e de la constante | 0;SUELIVAN; et al; Comparison of two methods of preparing enzyme-antibody conjugates: application of these | |
| William . | | Conjugates for enzyme impurescent "A distribution of these | |
| | | conjugates for enzyme immunoassay," Anal. Biochem. 100(1):100-08 (1979). | |
| | | DIFCAMAN A 1 70 | |
| | | RIEGMAN, et al. "Characterization of the prostate specific antigen gene: a novel human kallikrein-like gene," | _ |
| THE STATE OF THE STATE OF | Residence of | Biochem. Biophys. Res. Commun. 159(1):95-102 (1989). | |
| | | | |
| | | | |

Examiner's Signature Date Considered 4/2/0/
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPER 600. Described the second of t

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

| . PT | O/SB/08A (10-96 |
|--|-----------------|
| Approved for use through 10/31/99 | OMB ACE LOOM |
| Patent and Trademark Office: U.S. DEPARTMENT | OF COMMERCE |

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC Substitute for form 1449A/PTO

| Substitute for form 1449A/PTO | | in one control number | | |
|---------------------------------------|------------------------|-----------------------|--|--|
| | Complete if Known | | | |
| INFORMATION DISCLOSURE | Application Number | 09/445,865 | | |
| RE STATEMENT BY APPLICANT | | | | |
| | | | | |
| 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | Filing Date | February 11, 2000 | | |
| WHY BEET | First Named Inventor | Philip John Burke | | |
| | Group Art Unit | 1643 | | |
| hee ATENT & TRANS | Examiner Name | | | |
| neer of 9 | Attorney Docket Number | ERD 100 | | |

| | | OTHER ART NON PATENT LITERATURE DOCUMENTS | |
|---|----------------------|---|----|
| Examiner's | Cite | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the | |
| Initials* | No.1 | ntern (book, magazine, journar, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T |
| *************************************** | A COLUMN TO SERVED A | SAIKI, et al., "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase," Science 239(4839):487-91 (1988). | |
| VersionEdC | <u>arakin</u> | SAMBROOK, et al., Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor: New York (1989) | |
| · | -Contracti | SCHREWE, et al., "Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression," Mol. Cell. Biol. 10(6):2738-48 (1990). | ~- |
| ALC: THE | | SHARMA, et al., "Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model," Br. J. Cancer., 61(5):659-62 (1990). | |
| GW | | SHERWOOD, "Advanced drug delivery reviews: enzyme prodrug therapy," Adv. Drug Del. Rev. 22:269-88 (1996). | |
| | State State | SKERRA, et al., "Assembly of a functional immunoglobulin Fv fragment in Escherichia coli," <i>Science</i> 240(4855):1038-41 (1988) | |
| 92057893 | nostr. | TROWELL, "The cytocidal action of mitotic poisons on lymphocytes in vitro," Biochemical Pharmacology 5:53-63 | |
| ~ | | WAGNER, et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells," <i>Proc. Natl. Acad. Sci. U.</i> | |
| x-arrests c | 352 147 | WARD, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia oli," Nature 341(6242):544-46 (1989). | |
| A GOOD BOOK S | CH #XXX | MHISSON×& © ONNORS, "Cure of mice bearing, advanced plasma cell tumours with aniline mustard," Nature 206(985):689-91 (1965). | |

| | | | | | _ | / | <u> </u> | | |
|------------|----------------|-------------|-----------------|--------------|---------------|----------------|----------|-------------|--|
| Examiner's | | · | | | // | ′ ′ | / | | |
| Signature | / - | 2. 1 | Date Considered | CL | \mathcal{I} | $\overline{7}$ | . / | | |
| | (b | 2018 100 CB | | Ψ | // | ~ / <i>i</i> | 71 | | |
| | -0 | | | / | ı. | -/` | - | | |
| *EVALUED | | | | | | | | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of Translation is attached.

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box →

| Under the Pa | perwork F | Reduction Act of | f 1995, no pe | rsons are required to respond | to a collection of information unless it contains a va | alid OMB control number | OOMMEN |
|---|------------------|--|------------------------|--------------------------------|---|--|-------------|
| | Substit | ute for form | 1449A/P | го | 1 | | |
| | | | | | C | omplete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | DISCLOSURE APPLICANT | Application Number | 09/445,865 | |
| | | (use as m | any sheet | s as necessary) | | | |
| - 14 T | کے علاق | 2 | | | Filing Date | February 11, 2000 | |
| 0 12. | 7 | | | | First Named Inventor Group Art Unit | Philip John Burke | |
| Nr. | S. | , | | | Examiner Name | 1643 | |
| Sheet | 8 9 | | of | 9 | Attorney Docket Number | ERD 100 | |
| | | | | | | | |
| Examiner's | Cite | | | OTHER ART - 1 | NON PATENT LITERATURE DOCUM | ENTS | |
| Initials* | No. ¹ | | | , (500%, magazine, journal | (in CAPITAL LETTERS), title of the article (, serial, symposium, catalog, etc.), date, pa publisher, city and/or country where publish | ge(s), volume-issue number(s), | T² |
| | | WINTER & | MILSTEI | V, "Man-made antibo | dies," Nature 349(6307):293-99 (1 | 991). | |
| (************************************ | | | | | | | |
| لفنا فالفتاء بعيس ر | water street (| NU, et al., dependent* | "Catalyti oxidoredi | c properties of NAD(| P)H:quinone oxidoreductase-2 (NQC m.: Biophys. 347(2):221-28 (1997) | D2), a dihydronicotinamide riboside | _ |
| | | | | | | | 1 |
| | | CULA, "Mo | noclonal | Antibodies Amanua | of techniques," (CRC Press, 1988) |). | -+- |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | 1 |
| | ŀ | | | | | | |
| | | | | | | | |
| | | | | | | | |
| ļ | | | | | | | |
| | | | | | | | - |
| ŀ | [| | | | | | |
| | _ | | | | | | |
| | | | | - | | | +- |
| | | | | | | | ļ |
| | | ······································ | | | | | |
| 1 | | | | | | · | |
| | | | | | | | |
| aminer's | | | 0 1 | | Data Caralit | | |
| gnature | | M | <u>4</u> | | Date Considere | 9/2/0/ | |
| XAMINER: | Initial if n | eference con | sidered w | ethor or not cit-ti : : | conformance with MPEP 609. Draw line th | | |
| lude copy o | 6 Alb 6- | | Jacksu, WI | icardi di nol citation is in c | conformance with MPEP 609. Draw line the | rough citation if not in conformance and and | |

lude copy of this form with next communication to applicant. not in conformance and not considered.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1022153v1

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of Translation is attached.

Translation is attached.